Pharma Journalist 9038 posts 0 comments

Alpine Immune Sciences, Inc. and AbbVie Inc. announced an exclusive worldwide option and license agreement for ALPN-101, a first-in-class dual CD28/ICOS costimulation antagonist.…
Read More...

Sarepta Therapeutics and Selecta Biosciences, Inc. announced that they have entered into a Research License and Option agreement granting Sarepta an option to license the rights to…
Read More...

Roche announced that the Phase III IMpassion031 study, evaluating Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane, albumin-bound paclitaxel; nab-paclitaxel; followed…
Read More...

Neurocrine Biosciences, Inc. and Takeda Pharmaceutical Company Limited announced a strategic collaboration to develop and commercialize compounds in Takeda’s early-to-mid-stage…
Read More...

Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA),…
Read More...

Orca Bio, a clinical-stage biotechnology company developing high precision allogeneic cell therapies, announced a Series D financing that brings its total capital raised since its 2016…
Read More...

Cell-based cancer vaccines are revolutionizing the treatment of previously incurable cancers. Access to these promising therapies is limited by the high costs of manufacturing at…
Read More...

ISA Pharmaceuticals B.V., a private clinical-stage immunotherapy company, announced plans to initiate a potentially pivotal clinical trial for the combination of ISA101b and Libtayo…
Read More...

Lassen Therapeutics announced it has emerged from stealth and secured $31 million in Series A financing to develop antibodies as potential treatments for fibrosis, rare diseases and…
Read More...

PDS Biotechnology Corporation announced a co-development agreement with Farmacore Biotechnology for Versamune-CoV-2FC, a Versamune-based vaccine aimed at preventing COVID-19 infection.…
Read More...